Rahul Kumar

List of Publications by Year
in descending order

38 papers	3,692 citations	212478 28 h-index	340414 39 g-index
39 all docs	39 docs citations	39 times ranked	5924 citing authors

#	Article	IF	Citations
1	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. Journal of the National Cancer Institute, 2021, 113, 742-751.	3.0	98
2	Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development. Npj Breast Cancer, 2021, 7, 45.	2.3	7
3	Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	38
4	Sclerosing epithelioid mesenchymal neoplasm of the pancreasÂâ€"Âa proposed new entity. Modern Pathology, 2020, 33, 456-467.	2.9	10
5	Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome. Journal of Experimental Medicine, 2020, 217, .	4.2	117
6	Homologous recombination DNA repair defects in PALB2-associated breast cancers. Npj Breast Cancer, 2019, 5, 23.	2.3	39
7	The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers. JNCI Cancer Spectrum, 2019, 3, pkz027.	1.4	20
8	Genomic analysis of recurrences and highâ€grade forms of polymorphous adenocarcinoma. Histopathology, 2019, 75, 193-201.	1.6	10
9	Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway. Molecular Oncology, 2019, 13, 1684-1692.	2.1	21
10	The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. Human Pathology, 2019, 88, 66-77.	1.1	38
11	Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. Gynecologic Oncology, 2019, 152, 11-19.	0.6	66
12	The Genomic Landscape of Mucinous Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 737-741.	3.0	68
13	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. Journal of the National Cancer Institute, 2018, 110, 1030-1034.	3.0	90
14	E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. Cancer Discovery, 2018, 8, 498-515.	7.7	79
15	<i>MYBL1</i> rearrangements and <i>MYB</i> amplification in breast adenoid cystic carcinomas lacking the <i>MYB</i>â€"<i>NFIB</i> fusion gene. Journal of Pathology, 2018, 244, 143-150.	2.1	74
16	Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. Nature Communications, 2018, 9, 3533.	5.8	92
17	Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. Gynecologic Oncology, 2018, 150, 127-135.	0.6	41
18	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nature Communications, 2018, 9, 1816.	5.8	105

#	Article	IF	Citations
19	Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. Oncogene, 2018, 37, 5701-5718.	2.6	24
20	Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. British Journal of Cancer, 2017, 117, 113-123.	2.9	84
21	Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways. Npj Breast Cancer, 2017, 3, 40.	2.3	52
22	Prediction of anticancer molecules using hybrid model developed on molecules screened against NCI-60 cancer cell lines. BMC Cancer, 2016, 16, 77.	1.1	39
23	Managing Drug Resistance in Cancer: Role of Cancer Informatics. Methods in Molecular Biology, 2016, 1395, 299-312.	0.4	12
24	An in silico platform for predicting, screening and designing of antihypertensive peptides. Scientific Reports, 2015, 5, 12512.	1.6	123
25	Identification and characterization of novel protein-derived arginine-rich cell-penetrating peptides. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 89, 93-106.	2.0	35
26	Peptide Toxicity Prediction. Methods in Molecular Biology, 2015, 1268, 143-157.	0.4	105
27	Computer-Aided Virtual Screening and Designing of Cell-Penetrating Peptides. Methods in Molecular Biology, 2015, 1324, 59-69.	0.4	56
28	Enhancement of COPD biological networks using a web-based collaboration interface. F1000Research, 2015, 4, 32.	0.8	22
29	Enhancement of COPD biological networks using a web-based collaboration interface. F1000Research, 2015, 4, 32.	0.8	29
30	Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients. Scientific Reports, 2014, 4, 4483.	1.6	40
31	Designing of promiscuous inhibitors against pancreatic cancer cell lines. Scientific Reports, 2014, 4, 4668.	1.6	19
32	In silico approaches for designing highly effective cell penetrating peptides. Journal of Translational Medicine, 2013, 11, 74.	1.8	242
33	Computational approach for designing tumor homing peptides. Scientific Reports, 2013, 3, 1607.	1.6	69
34	CancerDR: Cancer Drug Resistance Database. Scientific Reports, 2013, 3, 1445.	1.6	102
35	In Silico Models for Designing and Discovering Novel Anticancer Peptides. Scientific Reports, 2013, 3, 2984.	1.6	226
36	In Silico Approach for Predicting Toxicity of Peptides and Proteins. PLoS ONE, 2013, 8, e73957.	1.1	1,120

#	Article	IF	Citations
37	CPPsite: a curated database of cell penetrating peptides. Database: the Journal of Biological Databases and Curation, 2012, 2012, bas015-bas015.	1.4	161
38	TumorHoPe: A Database of Tumor Homing Peptides. PLoS ONE, 2012, 7, e35187.	1.1	118